INDEPENDENT EXPLAINERS & GENERAL KNOWLEDGEKnow more. Think clearly.
Health & Education · AI-assisted explainer

New Covid Variant PJ.2.1 Explained: What We Know About Its Spread, Symptoms and Severity

PJ.2.1, a new SARS-CoV-2 lineage first sampled in Ontario, Canada, on 2 May 2026, is spreading in several countries and is being closely monitored, but researchers have found no evidence so far that it causes more severe disease.

By · Published · Updated · 10 min read

The short answer

PJ.2.1 is a lineage of SARS-CoV-2, the virus that causes COVID-19, first documented in a sample collected in Ontario, Canada, on 2 May 2026. It descends from MC.10.1.7, part of the JN.1 lineage, and researchers have described it as a “saltation variant” because its spike protein carries an unusually large number of mutations. A study by Markus Hoffmann and colleagues, published in the Journal of Infection on 24 October 2026, found that it binds more efficiently to the ACE2 receptor in laboratory experiments, and surveillance data from Ontario show its share of sequenced samples rising to 25.2 per cent. At the same time, the study found no substantially greater evasion of vaccine-induced antibodies, and there is currently no evidence that PJ.2.1 causes more severe illness, hospitalisation or death than other circulating variants.

What PJ.2.1 is, and where it was first found

PJ.2.1 is a lineage of SARS-CoV-2, the virus responsible for COVID-19. It was first detected in Ontario, Canada, on 2 May 2026, and was subsequently reported in other Canadian provinces. According to research published by Markus Hoffmann and colleagues in the Journal of Infection in October 2026, PJ.2.1 originated from MC.10.1.7, a descendant of the JN.1 lineage that circulated until May 2025. The variant has since been detected in the United States, Spain, France, Singapore, Australia, New Zealand and Israel.

In the United States, the first detection was in New York City on 30 June 2026, and subsequent detections were reported across several states, including California, Florida, Arizona and New Jersey. Based on wastewater surveillance, the researchers described PJ.2.1 as the “fastest-growing variant in the USA” at the time of the study. Beyond North America, sequences of the variant were reported in Singapore, Australia, New Zealand, Israel, France and Spain, suggesting that its spread is not confined to one region.

The study also examined other SARS-CoV-2 variants, including BA.3.2.2, LP.8.1, NB.1.8.1 and XFG, along with their descendants. It found that BA.3.2.2 had a relatively high frequency across the regions analysed between May and June 2026, although its prevalence subsequently began to decline. PJ.2.1 is the lineage that has drawn the most attention since then, because its share of sequenced samples has kept rising while other lineages have fallen back.

Why scientists call it a “saltation variant”

Researchers have described PJ.2.1 as a “saltation variant”, a term used for a virus that emerges with an unusually large number of genetic changes compared with its earlier form, rather than accumulating mutations gradually. The key difference lies in its genetic changes and its interaction with human cells. As Dr Amit Saraf, director of internal medicine at Jupiter Hospital Thane, told the Indian Express, the October 2026 Journal of Infection study found that PJ.2.1 has a highly mutated spike protein and showed an increased ability to interact with the ACE2 receptor, which the virus uses to enter human cells.

The spike protein is the structure on the surface of the coronavirus that helps it attach to and enter human cells, and the ACE2 receptor is the doorway it uses. A variant with many changes to its spike protein is watched closely for two reasons: the changes might help it enter cells more efficiently, and they might help it escape antibodies built up from earlier infection or vaccination. Those are possibilities to test, not conclusions, and the Hoffmann study tested both of them in the laboratory.

Dr Harish Chafle, senior consultant chest physician at Gleneagles Hospitals Parel in Mumbai, explained to the Indian Express that PJ.2.1 is a saltation variant because it has many new mutations in the spike protein, which help it attach better to human cells and escape some old immunity. That explanation captures why the label sounds alarming, but the label itself describes the pattern of mutations, not the severity of the disease. A variant can look very different genetically and still cause the same kind of illness as its predecessors.

Where it has been found, and how fast it is growing

PJ.2.1 has been detected across North America, Europe, Asia and Oceania. The countries named in the reporting read for this article are Canada, the United States, Spain, France, Singapore, Australia, New Zealand and Israel. In the United States, detections were reported in New York City first and then in states including California, Florida, Arizona, New Jersey, Virginia, North Carolina, Missouri, Oklahoma, Colorado and Florida. In Spain, researchers reported signs of sustained local transmission across different regions.

The clearest measure of its growth comes from Ontario, where Public Health Ontario’s genomic surveillance data showed that PJ.2.1 accounted for 25.2 per cent of sequenced SARS-CoV-2 samples between 20 September and 17 October 2026, up from 16.9 per cent in the preceding four-week period. Those figures describe the share of sequenced samples, not the share of all infections, because only a fraction of cases are sequenced. Even so, a rise from 16.9 per cent to 25.2 per cent across consecutive four-week windows, alongside the wastewater finding that it was the fastest-growing variant in the United States, is why surveillance bodies are watching it closely.

The World Health Organization and international surveillance bodies are closely monitoring PJ.2.1’s growth advantage over other circulating strains, according to News18. That monitoring does not mean the variant has been given a formal classification: the WHO’s variant-tracking framework assesses emerging lineages on their genetic characteristics and their potential public health implications, and whether PJ.2.1 has been added to any WHO list could not be verified from the pages opened for this article. What is established is that the variant is spreading across several countries at the same time, which is the reason it is being tracked.

What the laboratory research found, and what it did not

The research that put PJ.2.1 on the map is a study by Markus Hoffmann and colleagues, published in the Journal of Infection on 24 October 2026, titled “Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1”. The study examined the variant’s genetic characteristics, its ability to enter human cells and its susceptibility to antibodies. Laboratory experiments indicated greater cell-entry efficiency in certain cell lines, and the researchers found that PJ.2.1 binds more efficiently to the ACE2 receptor. The study also found that PJ.2.1 was less susceptible to inhibition by an antibody targeting ACE2 than the other variants examined.

On the question of immunity, the findings were reassuring in an important way. The study did not find that PJ.2.1 was substantially better at escaping antibodies generated by variant-adapted vaccine responses than most other variants examined. Antibodies from people who had received an LP.8.1-adapted COVID-19 vaccine were still capable of neutralising PJ.2.1. As Dr Saraf told the Indian Express, this is an important distinction: a variant spreading faster does not necessarily mean it causes more severe disease, and its clinical behaviour, including the possibility of increased hospitalisations, still needs to be established through real-world data.

The limits of the research matter as much as its findings. The experiments were conducted in laboratory models, and they do not establish how efficiently PJ.2.1 spreads between people or whether it causes more severe illness in real-world conditions. The Journal of Infection study primarily examined genetic characteristics, cell entry and susceptibility to antibodies; it did not establish an increase in disease severity, hospitalisations or deaths among infected patients. At present, there is insufficient clinical evidence to conclude that PJ.2.1 causes more severe COVID-19 or increases the risk of hospitalisation and death. Some reporting of the study has described its findings as preliminary, and readers should note that the peer-reviewed paper appeared on 24 October 2026; the date of any earlier preprint version could not be verified from the pages opened for this article.

Symptoms: why they look like flu and a cold

PJ.2.1 does not have a unique set of symptoms that distinguishes it from other COVID-19 variants. Its symptoms look just like a common cold or seasonal flu. Patients report fever, severe sore throat, runny or blocked nose, cough, headache, muscle ache and fatigue, according to Dr Chafle. A smaller subset of patients report loss of taste or smell, breathlessness and mild gastrointestinal issues. Because of this overlap, a person cannot tell from symptoms alone whether an infection is COVID-19, flu or a cold.

The World Health Organization has highlighted that COVID-19 symptoms often resemble those of influenza and other respiratory infections, making it challenging to differentiate between them based on symptoms alone. The general coronavirus symptoms identified by the WHO include fever or chills, cough, sore throat, runny or blocked nose, headache, pain in muscles and body, and fatigue and weakness. Other possible symptoms include breathlessness, gastrointestinal issues or changes in the sense of smell and taste.

That overlap is why testing matters. As Dr Chafle told the Indian Express, the WHO says testing is important when treatment decisions depend on it. A diagnostic antigen or PCR test can establish whether an infection is caused by SARS-CoV-2, while genomic sequencing is required to confirm that a specific infection is caused by PJ.2.1. In practice, that means most people who catch PJ.2.1 will never know which lineage infected them, and the clinical advice is the same as for any respiratory infection: rest, monitor symptoms, and seek medical advice if they worsen.

Vaccines, immunity and who should be careful

The laboratory evidence so far suggests that existing immunity still works against PJ.2.1. Neutralisation assays indicate that the variant does not demonstrate augmented evasion of antibodies generated by recent updated COVID-19 vaccines, and antibodies from people who received an LP.8.1-adapted vaccine were able to neutralise it. News18 reported that health organisations stress that existing public health measures, diagnostic tests and updated vaccines remain effective tools for protection. That is a laboratory finding, and real-world protection against infection and severe disease still needs to be confirmed through clinical data.

The researchers reported that detection of PJ.2.1 was more frequent in older age groups, particularly individuals aged 70 and over. That observation does not establish that the variant specifically targets the elderly or causes more severe disease in that age group, and it may partly reflect who gets tested and sequenced. Even so, the doctors quoted in the Indian Express were consistent that older adults and people with underlying conditions should be more careful. Dr Chafle advised that high-risk elderly people should be more careful, and Dr Saraf said older adults, people with diabetes, heart or lung conditions, and those with weakened immunity are more vulnerable to complications from respiratory infections.

The precautions recommended are familiar ones. Dr Chafle advised wearing a mask in crowded closed places, testing if symptoms last more than two days, isolating, and consulting a doctor in case of fever with breathlessness or low oxygen. Dr Saraf advised wearing a well-fitting mask in crowded or poorly ventilated spaces, maintaining indoor ventilation and practising hand hygiene, and said those at higher risk should discuss their vaccination status and any need for an updated dose with their treating physician. The message from both doctors was the same: remain informed, avoid panic, and focus on early recognition, responsible precautions and timely medical care rather than fear of every new variant.

What it means for India

For readers in India, the most important fact is a negative one: it remains unclear whether PJ.2.1 has been detected in India, as there is no confirmed evidence of that as of now. The Indian SARS-CoV-2 Genomics Consortium, known as INSACOG, monitors genetic changes in circulating coronavirus strains through genomic sequencing, and that surveillance is the route by which any Indian detection would be identified. Until INSACOG or another authoritative source confirms a detection, the variant should not be described as present in India.

That does not mean India can ignore it. COVID-19 continues to circulate globally and remains a cause of considerable illness and death, as the researchers noted in the Journal of Infection paper, and international travel facilitates the global presence of new lineages. The variant’s spread across eight countries, its growth in Ontario and its faster growth in US wastewater surveillance are all reasons for Indian surveillance to keep watching, even though no Indian detection has been confirmed.

The practical advice for Indians, as given by the doctors quoted in the Indian Express, is proportionate. There is no need to panic, according to Dr Chafle, but people should wear a mask in crowded closed places, test if symptoms last more than two days, isolate if ill, and consult a doctor if they develop fever with breathlessness or low oxygen. Older adults and people with diabetes, heart or lung conditions or weakened immunity should be particularly careful. The emergence of another variant is a reminder that respiratory infections require continued attention, but on the evidence available today, PJ.2.1 is a variant to monitor, not a reason for alarm.

Editorial disclosure

This article was researched with AI assistance and reviewed by the publisher before publication. Report factual errors through our contact page.

Frequently asked questions

What is PJ.2.1?

PJ.2.1 is a lineage of SARS-CoV-2, the virus that causes COVID-19. It descends from MC.10.1.7, part of the JN.1 lineage, and was first documented in a sample collected in Ontario, Canada, on 2 May 2026. Researchers describe it as a “saltation variant” because its spike protein carries an unusually large number of mutations.

What are the symptoms of PJ.2.1?

There is no unique symptom profile for PJ.2.1. Reported symptoms are the same as for other COVID-19 variants and overlap heavily with flu and the common cold: fever, cough, sore throat, runny or blocked nose, headache, muscle aches and fatigue, with some people reporting loss of taste or smell, breathlessness or mild gastrointestinal issues. Only a test can identify COVID-19, and only genomic sequencing can confirm PJ.2.1.

Has PJ.2.1 been detected in India?

There is no confirmed evidence of PJ.2.1 being detected in India as of now. The Indian SARS-CoV-2 Genomics Consortium (INSACOG) monitors circulating strains through genomic sequencing, and any Indian detection would be identified through that surveillance.

Do vaccines still work against PJ.2.1?

Laboratory research found no substantially greater evasion of vaccine-induced antibodies than in most other variants examined, and antibodies from people who received an LP.8.1-adapted COVID-19 vaccine were able to neutralise PJ.2.1. Real-world protection still needs to be confirmed through clinical data, and people at higher risk should discuss their vaccination status with their doctor.

Should I be worried about PJ.2.1?

On current evidence, no. Researchers have found no evidence that PJ.2.1 causes more severe illness, hospitalisation or death than other circulating variants. It is spreading and is being closely monitored, so sensible precautions apply: mask in crowded closed places, test if symptoms persist, isolate when ill, and seek medical advice if symptoms worsen.

Sources & further reading

Sources reviewed 2026-11-12. Official statements describe the issuing organisation’s position; this article is an independent explainer.

Suggest a correction · More in Health & Education

Keep exploring